Pressmeddelande —
Otsuka Presents Final Phase 3 VISIONARY Results at ASN Demonstrating Sibeprenlimab Stabilised Kidney Function and Reduced Risk of Disease Progression and Kidney Failure in IgA Nephropathy
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY
Otsuka Presents Final Phase 3 VISIONARY Results at ASN Demonstrating Sibeprenlimab Stabilised Kidney Function and Reduced Risk of Disease Progression and Kidney Failure in IgA Nephropathy
- Results from the Phase 3 VISIONARY trial showed a 97% reduction in the risk of a composite kidney outcome event of kidney function decline or kidney failure in patients treated with sibeprenlimab compared with placebo over two years (secondary endpoint).1
- VISIONARY demonstrated sustained preservation of kidney function over two years (secondary endpoint), supporting the role of selective APRIL inhibition as a disease-modifying treatment in IgAN.1
- The overall safety profile of sibeprenlimab remained consistent to placebo.1
- Final results were published in The New England Journal of Medicine.
Windsor, United Kingdom, – October 23, 2026 - Otsuka Pharmaceutical Europe Ltd. (Otsuka) today announced the final two-year (24-month) results from the Phase 3 VISIONARY study demonstrating sustained preservation of kidney function with sibeprenlimab in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression.1 Treatment with sibeprenlimab stabilised kidney function and reduced the risk of a composite kidney outcome event of kidney function decline or kidney failure compared with placebo by 97%.1 With the largest patient population evaluated through two years in a placebo-controlled trial, VISIONARY provides a substantial and robust body of evidence and is the first Phase 3 IgAN study to achieve the 2025 KDIGO treatment goal of slowing kidney function decline to near-physiologic rates (eGFR decline <1 mL/min/1.73 m²/year for many adults).1,2 These findings support selective APRIL inhibition as a disease-modifying therapeutic approach targeting a key driver of IgAN pathogenesis.1,3 These data were presented today at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, as a featured oral presentation during the Opening Plenary Session, as a late-breaking poster presentation, and within the ASN press programme. These findings were published simultaneously in The New England Journal of Medicine.
Among 510 randomised patients, progression to the composite kidney function outcome (secondary endpoint defined as meeting any one or more of the following events: sustained doubling of serum creatinine compared with baseline for 2 measurements with at least 4 weeks apart, sustained 40% reduction in eGFR compared with baseline for 2 measurements with at least 4 weeks apart, sustained eGFR < 15 mL/min/1.73m2 for 2 measurements with at least 4 weeks apart or the requirement of renal replacement therapy) occurred in 1 of 259 patients receiving sibeprenlimab (0.4%) compared with 28 of 251 patients receiving placebo (11.2%), representing a 97% lower hazard (HR 0.029, 95% CI 0.004 to 0.214, p<0.0001) of a composite kidney outcome.1,4 Compared with placebo, fewer patients receiving sibeprenlimab experienced a sustained eGFR decline of at least 40% (1 vs 28), sustained doubling of serum creatinine (0 vs 13), or sustained eGFR below 15 mL/min/1.73 m² (1 vs 10).1 No patients receiving sibeprenlimab initiated kidney replacement therapy compared with 5 receiving placebo.1 At two years, the least square mean change from baseline in eGFR showed +1.3 mL/min/1.73 m² with sibeprenlimab (95% CI, −0.3 to 2.8), compared with −7.9 mL/min/1.73 m² with placebo (95% CI, −9.5 to −6.4), resulting in a relative group treatment difference of +9.2 mL/min/1.73 m² (95% CI, 7.1 to 11.4; p<0.0001).1 VISIONARY had previously met its primary endpoint of reduction in 24-hour uPCR at 9 months compared with baseline.3
The overall safety profile of sibeprenlimab remained consistent through two years, with similar rates of overall treatment-emergent adverse events (90.7% vs 90.0%), infections and infestations (51.4% vs 51.0%), and injection site reactions compared to placebo.1 No new safety signals were identified from earlier analyses, and rates of serious infections were lower with sibeprenlimab than placebo (1.9% vs 4.0%), alongside lower rates of serious and severe adverse events and treatment discontinuations.1
Otsuka would like to thank the patients, families, advocates, and investigators who participated in the VISIONARY study and whose commitment and perseverance made this research possible.
About the VISIONARY Study3,5
VISIONARY (NCT05248646) is a global, randomised, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of sibeprenlimab in adults with primary IgAN at risk of disease progression. The primary efficacy endpoint assessed proteinuria reduction, as measured by the change in 24-hour urine protein-to-creatinine ratio (uPCR-24h) from baseline compared with placebo after nine months of treatment. The key secondary endpoint evaluated annualised eGFR slope over 24 months (two years), providing an assessment of kidney function over time. The least square mean change from baseline in eGFR at month 24 was also evaluated as a secondary endpoint, offering a complementary measure of overall treatment effect at a defined timepoint. This programme continues to advance the science in IgAN, with future data forthcoming in an open-label, long-term extension study (NCT05248659).
About IgAN
IgA nephropathy (IgAN) is a progressive, immune-mediated, chronic kidney disease that typically manifests in adults aged under 40 years and can lead to kidney failure (KF) over the lifetime of many patients.6,7,8 IgAN is characterised by the accumulation of Gd-IgA1 complexes in the kidneys.9 IgAN can lead to progressive loss of kidney function and, eventually, KF, imposing a significant burden on patients.9 Despite supportive care, there is an unmet need for treatments that address the root causes of the condition.9 Continued research in IgAN remains crucial to uncovering opportunities for advancement in our understanding and treatment of patients.9
About sibeprenlimab
Sibeprenlimab is a humanised monoclonal antibody that binds to and blocks APRIL, which plays a key role in the widely accepted 4-hit process of IgAN pathogenesis and is an important initiating and sustaining factor in IgAN progression by promoting the production of pathogenic galactose-deficient IgA1 (Gd-IgA1).3,9,10 Inhibition of APRIL results in reduced levels of serum galactose-deficient IgA1 (Gd-IgA1), which is implicated in the pathogenesis of IgAN.3 In Europe, sibeprenlimab was granted orphan designation by the European Commission for the treatment of primary IgAN in 2021.11 In Europe and the UK, sibeprenlimab is not approved for use by the regulatory authorities.
About Otsuka
Otsuka Pharmaceutical Co., Ltd. is a total healthcare company that focuses on each individual’s potential to enhance their well-being. Our medical-related business provides treatments and diagnostics for both physical and mental health. Our nutraceutical business supports daily health maintenance and improvement. Otsuka’s products and services are based on scientific evidence, under the guidance of our corporate philosophy: Otsuka-people creating new products for better health worldwide. Otsuka Europe employs around 500 people and focuses on psychiatric and neurologic disorders, nephrology and immunology, haemato-oncology, and digital therapeutics.
Otsuka Pharmaceutical Europe Ltd. is a part of Otsuka Pharmaceutical Company, Ltd., a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. For further information on Otsuka, please visit www.otsuka-europe.com.
Otsuka and the Otsuka logo are registered trademarks of Otsuka Holdings Co., Ltd. or its subsidiaries.
Contacts for Media
Otsuka in the EU
Alison Ross
Otsuka Pharmaceutical Europe Ltd. ARoss@Otsuka-Europe.com
+44 776 833 7128
References
1. V. Perkovic et al. Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis, N Engl J Med. Oct 22, 2026 DOI: 10.1056/NEJMoa2609127
2. Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025;108(4S):S1-S71.
3. Perkovic V, et al. Sibeprenlimab in IgA nephropathy: Interim analysis of a phase 3 trial. N Engl J Med. 2026;394(7):635–646.
4. Perkovic V, et al. Evaluating sibeprenlimab in IgA nephropathy: Rationale and baseline data from the VISIONARY trial. Kidney Int Rep. 2025;10(12):4207–4218.
5. ClinicalTrials.gov. NCT05248646. A Study of Sibeprenlimab in Participants With Immunoglobulin A Nephropathy (IgAN) (VISIONARY).
6. Pitcher, D. et. al., Long-term outcomes in IGA nephropathy. Clin J Am Soc Nephrol. 2023 Jun 1;18(6):727-738.
7. Cheung CK, et al. Evaluation and management of IgA nephropathy. Clin Med. 2012;12(Suppl 6):s27–s30.
8. Lai KN, et al. IgA nephropathy. Nat Rev Dis Primers. 2016;2:16001.
9. Cheung CK, et al. The role of BAFF and APRIL in IgA nephropathy: Pathogenic mechanisms and targeted therapies. Front Nephrol. 2024;3:1346769.
10. Chang S, et al. The role of immune modulation in pathogenesis of IgA nephropathy. Front Med. 2020;7:92.
11. European Medicines Agency. Orphan designation for treatment of primary IgA nephropathy. 2021.
OPE-SIB-2600027 v1.0 | NOR-SIB-2600001 v 1.0 (10/2026)